Dengue Vaccines and Antivirals Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Dengue Vaccines and Antivirals remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 158 matched trial records and 74 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07600879 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | Brazil | Muscle fatigue assessed by surface electromyography (Baseline and immediately after completion of the intervention protocol) | 2027-07-01 |
| NCT07602920 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Oxford | Bangladesh | Level of gut leakage marker in blood and gastrointestinal findings in POCUS (On enrollment, day of development of severity if non severe at enrolment, up…) | 2027-01-31 |
| NCT07576868 | Niclosamide | Phase 2/3; Recruiting | HYUNDAI BIOSCIENCE Co., Ltd. | Vietnam | [Part 1] Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) (From start of study intervention (Day 1) up to end of safety follow-up (Day 29)); [Part 1] Average of dengue viral load on Day 3 (Baseline, Day 1, 2, 3) | 2027-01-01 |
| NCT07543458 | Baricitinib + Dexamethasone Sodium Phosphate + Acetylcysteine | Phase 3; Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | Colombia, Vietnam, Bangladesh, Philippines, Brazil +5 more | Progression to severe dengue/critical dengue (between randomization to hospital discharge (average of 5 days)); All-cause mortality within 30 days (Day 30) | 2030-07-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Phase 1 Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine (Phase 1): the indexed record reports Injection site pain = 4 Participants; Injection site pain = 0 Participants; Injection site pain = 0 Participants.
- Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial (Phase 2): the indexed record reports AE = Vaccine RNAemia and safety findings were consistent with the known TAK-003 safety profile.
- Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine (Phase 3): the indexed record reports VE(against DENV-1 (95% CI)) = 73.0 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Niclosamide (Phase 2/3), Baricitinib (Approved; JAK1 x JAK2), Dexamethasone Sodium Phosphate (Approved; GR), Acetylcysteine (Approved; Free radicals). Company & Deal Intelligence records identify sponsor context for University of Oxford, HYUNDAI BIOSCIENCE Co., Ltd. (048410), Oxford University Clinical Research Unit, Vietnam. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Dengue Vaccines and Antivirals has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
